.svg){kind=small}
Dec-2025
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
In the New York market, Canna Clinicals has shown a dynamic performance in the Tincture & Sublingual category. The brand maintained a consistent ranking at 8th place in September and October 2025, before experiencing a dip to 11th place in November. However, it rebounded to 9th place in December. This fluctuation indicates a competitive environment where Canna Clinicals is actively vying for a top position. The brand's sales in October were notably higher, reaching $35,720, suggesting a strong market presence during that period despite the subsequent ranking drop in November.
Notably, Canna Clinicals did not make it into the top 30 brands in other states or categories during this period, which could either highlight a strategic focus on the New York Tincture & Sublingual market or a potential area for growth and expansion. The absence from the top rankings in other regions or categories might suggest a need for diversification or enhancement of their offerings to capture a broader audience. This concentrated performance in New York could be both an opportunity and a challenge, as the brand may need to explore strategies for scaling their success beyond their current stronghold.
Competitive Landscape
In the competitive landscape of the Tincture & Sublingual category in New York, Canna Clinicals has experienced notable fluctuations in its market rank and sales performance from September to December 2025. Initially holding a strong position at rank 8 in September and October, Canna Clinicals saw a dip to rank 11 in November before recovering slightly to rank 9 in December. This volatility contrasts with the steady ascent of Ithaca Organics Cannabis Co., which improved its rank from 9 to 7 over the same period, indicating a consistent increase in consumer preference. Meanwhile, Harney Brothers Cannabis also demonstrated upward momentum, climbing from rank 11 in September to 8 by December. Despite Canna Clinicals' initial higher sales figures, the brand's sales dropped significantly in November, which may have contributed to its temporary rank decline. This competitive pressure suggests that Canna Clinicals needs to strategize effectively to regain and maintain its market position amidst the rising popularity of its competitors.
Notable Products
In December 2025, the top-performing product for Canna Clinicals was the CBD/THC 1:10 Max Strength Tincture (100mg CBD, 1000mg THC, 30ml) in the Tincture & Sublingual category, maintaining its first-place ranking for four consecutive months with sales of 338 units. The CBD/THC Unwind Tincture (1050mg CBD, 90mg THC, 15ml) also held steady in second place throughout the same period, showing consistent demand. The CBD/CBN/THC Sleep Tincture (300mg CBD, 300mg CBN, 150mg THC) climbed to third place in November and maintained that position in December, indicating growing popularity. Meanwhile, the CBD/THC 1:1 Max Strength Capsules 10-Pack saw a slight improvement, moving from fifth to fourth place from October to December. The CBD/THC/CBN 1:1:1 Sleep Complex Capsules 20-Pack remained stable in the fifth position, despite a decrease in sales figures over the months.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
